Medicina
Departamento
University of Bologna
Bolonia, ItaliaPublicaciones en colaboración con investigadoras/es de University of Bologna (24)
2024
-
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death
Scientific reports, Vol. 14, Núm. 1, pp. 3000
-
Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance
American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654
2023
-
Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations (Scientific Reports, (2023), 13, 1, (17235), 10.1038/s41598-023-43287-4)
Scientific Reports
-
Comparison of the management of Helicobacter pylori infection between the older and younger European populations
Scientific Reports, Vol. 13, Núm. 1
-
Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)
Gut, Vol. 72, Núm. 6, pp. 1054-1072
2022
-
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)
Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257
-
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Journal of Clinical Medicine, Vol. 11, Núm. 6
-
Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)
Journal of Clinical Gastroenterology, Vol. 56, Núm. 2, pp. E98-E108
2021
-
Antibiotic resistance prevalence and trends in patients infected with helicobacter pylori in the period 2013–2020: Results of the european registry on h. pylori management (hp-eureg)
Antibiotics, Vol. 10, Núm. 9
-
European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients
Gut, Vol. 70, Núm. 1, pp. 40-54
2018
-
Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals
Clinical Microbiology and Infection, Vol. 24, Núm. 10, pp. 1070-1076
-
Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome
Gastroenterology, Vol. 155, Núm. 1, pp. 168-179
-
Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients
Clinical Gastroenterology and Hepatology
2017
-
Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016
The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210
-
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016
The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150
-
Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015
The Lancet, Vol. 390, Núm. 10091, pp. 231-266
2016
-
Urate lowering therapies in the treatment of gout: A systematic review and meta-Analysis
European Review for Medical and Pharmacological Sciences, Vol. 20, Núm. 5, pp. 983-992
2015
-
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
The Lancet, Vol. 385, Núm. 9963, pp. 117-171
-
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
The Lancet, Vol. 386, Núm. 10010, pp. 2287-2323
-
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition
The Lancet, Vol. 386, Núm. 10009, pp. 2145-2191